Search Results - "Diekema, D.J"

Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria by Pfaller, M.A, Diekema, D.J, Andes, D, Arendrup, M.C, Brown, S.D, Lockhart, S.R, Motyl, M, Perlin, D.S

“…Abstract The CLSI established clinical breakpoints (CBPs) for caspofungin (CSF), micafungin (MCF) and anidulafungin (ANF) versus Candida. The same CBP…”
Get full text

Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida : Time for harmonization of CLSI and EUCAST broth microdilution methods by Pfaller, M.A, Andes, D, Diekema, D.J, Espinel-Ingroff, A, Sheehan, D

“…Abstract Background Both the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST)…”
Get full text

Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values by Pfaller, M.A, Chaturvedi, V, Diekema, D.J, Ghannoum, M.A, Holliday, N.M, Killian, S.B, Knapp, C.C, Messer, S.A, Miskou, A, Ramani, R

“…Abstract A commercially prepared dried colorimetric microdilution panel (Sensititre Yeast One, TREK Diagnostic Systems, Cleveland, OH, USA) was compared in 3…”
Get full text

In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program by Pfaller, M.A, Messer, S.A, Boyken, L, Hollis, R.J, Rice, C, Tendolkar, S, Diekema, D.J

“…We examined the in vitro activities of voriconazole, posaconazole, and fluconazole against 3,932 isolates of Candida spp. and 237 isolates of Cryptococcus…”
Get full text

In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents by Pfaller, M.A, Diekema, D.J, Messer, S.A, Boyken, L, Hollis, R.J, Jones, R.N

“…We determined the in vitro susceptibilities of 643 strains of Candida spp., representing 13 species rarely isolated from blood, to ravuconazole as well as…”
Get full text

In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs by Pfaller, M.A., Messer, S.A., Boyken, L., Hollis, R.J., Diekema, D.J.

“…The performance of the Etest for posaconazole susceptibility testing of 72 isolates of filamentous fungi was assessed in comparison with the National Committee…”
Get full text

Seasonality of staphylococcal infections by Leekha, S., Diekema, D.J., Perencevich, E.N.

“…Characterization of seasonal variation of Staphylococcus aureus is important in understanding the epidemiology of, and designing preventive strategies against…”
Get full text

An outbreak of Candida parapsilosis prosthetic valve endocarditis by Diekema, D.J., Messer, S.A., Hollis, R.J., Wenzel, R.P., Pfaller, M.A.

“…Candida parapsilosis, an important nosocomial pathogen and the most common species of Candida found on the hands of health care workers, is a rare cause of…”
Get full text

Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion by Pfaller, M.A, Diekema, D.J, Gibbs, D.L, Newell, V.A, Ellis, D, Tullio, V, Rodloff, A, Fu, W, Ling, T.A

“…Fluconazole in vitro susceptibility test results for 256,882 isolates of Candida spp. were collected from 142 sites in 41 countries from June 1997 to December…”
Get full text

In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance by Pfaller, M.A, Boyken, L, Hollis, R.J, Kroeger, J, Messer, S.A, Tendolkar, S, Diekema, D.J

“…The echinocandins are being used increasingly as therapy for invasive candidiasis. Prospective sentinel surveillance for the emergence of in vitro resistance…”
Get full text

Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Triazoles and Six Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document) by Espinel-Ingroff, A, Diekema, D.J, Fothergill, A, Johnson, E, Pelaez, T, Pfaller, M.A, Rinaldi, M.G, Canton, E, Turnidge, J

“…Clinical breakpoints have not been established for mold testing. Wild-type (WT) MIC distributions (organisms in a species/drug combination with no detectable…”
Get full text

Contamination of health-care workers' hands with Escherichia coli and Klebsiella species after routine patient care: a prospective observational study by Puig-Asensio, M., Diekema, D.J., Boyken, L., Clore, G.S., Salinas, J.L., Perencevich, E.N.

“…To compare the frequency of health-care worker (HCW) hand contamination by Escherichia coli versus Klebsiella species after patient care and to determine…”
Get full text

Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints by Pfaller, M.A, Diekema, D.J, Ostrosky-Zeichner, L, Rex, J.H, Alexander, B.D, Andes, D, Brown, S.D, Chaturvedi, V, Ghannoum, M.A, Knapp, C.C, Sheehan, D.J, Walsh, T.J

“…The CLSI Antifungal Subcommittee followed the M23-A2 "blueprint" to develop interpretive MIC breakpoints for anidulafungin, caspofungin, and micafungin against…”
Get full text

Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and Candida spp by Pfaller, M.A, Boyken, L, Hollis, R.J, Kroeger, J, Messer, S.A, Tendolkar, S, Jones, R.N, Turnidge, J, Diekema, D.J

“…We tested a global collection of Candida sp. strains against anidulafungin, caspofungin, and micafungin, using CLSI M27-A3 broth microdilution (BMD) methods,…”
Get full text

Activity of MGCD290, a Hos2 Histone Deacetylase Inhibitor, in Combination with Azole Antifungals against Opportunistic Fungal Pathogens by Pfaller, M.A, Messer, S.A, Georgopapadakou, N, Martell, L.A, Besterman, J.M, Diekema, D.J

“…We report on the in vitro activity of the Hos2 fungal histone deacetylase (HDAC) inhibitor MGCD290 (MethylGene, Inc.) in combination with azoles against…”
Get full text

Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing by Pfaller, M.A, Diekema, D.J, Gibbs, D.L, Newell, V.A, Bijie, H, Dzierzanowska, D, Klimko, N.N, Letscher-Bru, V, Lisalova, M, Muehlethaler, K, Rennison, C, Zaidi, M

“…Fluconazole in vitro susceptibility test results determined by the CLSI M44-A disk diffusion method for 11,240 isolates of noncandidal yeasts were collected…”
Get full text

Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-Year Analysis of Susceptibilities of Candida Species and Other Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing by Pfaller, M.A, Diekema, D.J, Gibbs, D.L, Newell, V.A, Meis, J.F, Gould, I.M, Fu, W, Colombo, A.L, Rodriguez-Noriega, E

“…Fluconazole in vitro susceptibility test results for 205,329 yeasts were collected from 134 study sites in 40 countries from June 1997 through December 2005…”
Get full text

Variation in Susceptibility of Bloodstream Isolates of Candida glabrata to Fluconazole According to Patient Age and Geographic Location in the United States in 2001 to 2007 by Pfaller, M.A, Messer, S.A, Hollis, R.J, Boyken, L, Tendolkar, S, Kroeger, J, Diekema, D.J

“…We examined the susceptibilities to fluconazole of 642 bloodstream infection (BSI) isolates of Candida glabrata and grouped the isolates by patient age and…”
Get full text

Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest Methods with the CLSI Broth Microdilution Method for Echinocandin Susceptibility Testing of Candida Species by Pfaller, M.A, Castanheira, M, Diekema, D.J, Messer, S.A, Moet, G.J, Jones, R.N

“…The antifungal broth microdilution (BMD) method of the European Committee on Antibiotic Susceptibility Testing (EUCAST) and the Etest agar diffusion method…”
Get full text

In Vitro Susceptibility of Clinical Isolates of Aspergillus spp. to Anidulafungin, Caspofungin, and Micafungin: a Head-to-Head Comparison Using the CLSI M38-A2 Broth Microdilution Method by Pfaller, M.A, Boyken, L, Hollis, R.J, Kroeger, J, Messer, S.A, Tendolkar, S, Diekema, D.J

“…We determined the in vitro activities of anidulafungin, caspofungin, and micafungin against 526 isolates of Aspergillus spp. (64 A. flavus, 391 A. fumigatus,…”
Get full text